Alzheimer’s Setback Makes Elan Takeover Bait to Biogen

Bad news for Elan Corp.’s Alzheimer’s drug is turning into good news for Biogen Idec Inc.’s takeover options.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.